CYBIN INC (CYBN) Stock News

USA - NYSEARCA:CYBN - CA23256X4075 - Common Stock

6.08 USD

-0.13 (-2.09%)

Last: 10/3/2025, 8:04:01 PM

6.18 USD

+0.1 (+1.64%)

After Hours: 10/3/2025, 8:04:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CYBN Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

11 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

12 days ago - By: Cybin Inc.

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

13 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

18 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

22 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

23 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

24 days ago - By: The Schall Law Firm

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

25 days ago - By: Cybin Inc.

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

25 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

a month ago - By: Cybin Inc.

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

a month ago - By: Cybin Inc.

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: Yahoo Finance - Mentions: DB PEP UTHR STZ ...

Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint

a month ago - By: Cybin Inc.

Cybin to Participate in the Cantor Global Healthcare Conference 2025

a month ago - By: Cybin Inc.

Cybin Announces Senior Leadership Changes

a month ago - By: Cybin Inc.

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

2 months ago - By: Cybin Inc.

Cybin Announces Results of Annual Meeting of Shareholders

2 months ago - By: Cybin Inc.

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

2 months ago - By: Cybin Inc.

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

2 months ago - By: Cybin Inc.

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

3 months ago - By: Cybin Inc.

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

3 months ago - By: Cybin Inc.

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

3 months ago - By: Cybin Inc.

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

3 months ago - By: Cybin Inc.

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

4 months ago - By: Cybin Inc.

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

4 months ago - By: Cybin Inc.

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

4 months ago - By: Cybin Inc.

Cybin to Participate in the 2025 Psychedelic Science Conference

4 months ago - By: Benzinga

Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming

4 months ago - By: Cybin Inc.

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

4 months ago - By: Benzinga - Mentions: ATAI CMPS SEEL MNMD ...

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors

5 months ago - By: Cybin Inc.

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

5 months ago - By: Cybin Inc.

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

5 months ago - By: Cybin Inc.

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder